Linked Life Data

14737727

Source:http://linkedlifedata.com/resource/pubmed/id/14737727

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2004-1-22
pubmed:abstractText
The initial draining lymph node for a primary tumor is referred to as the "sentinel" node. Firstly adopted in the management of patients with cutaneous melanoma and breast cancer, it is now widely tested in cervical cancer. In patients with cervical cancer, lymph node status is the most important prognostic factor for survival. In patients with cervical cancer FIGO stage I and II pelvic lymph node metastases are expected in 0-16 and 24.5-31% and para-aortic lymph node metastases are expected in 0-22 and 11-19% of patients. The removal of pelvic and para-aortic lymph nodes is essential for assessing the biology of the disease. Lymphoscintigraphy enables the visualisation of lymphatic drainage patterns from a great variety of tumour sites prior to surgery. Therefore, the current procedure is to perform the pre-operative mapping of sentinel nodes by static and/or dynamic lymphoscintigraphy, followed by in vivo identification using a gamma detection probe and selective surgical resection.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1506-9680
pubmed:author
pubmed:issnType
Print
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
127-30
pubmed:dateRevised
2011-10-13
pubmed:meshHeading
pubmed:year
2003
pubmed:articleTitle
Use of Tc99m-nanocolloid for sentinel nodes identification in cervical cancer.
pubmed:affiliation
Department of Endocrinology, Nuclear Medicine Unit, Jagiellonian University, Kraków, Poland. alahuh@endo.cm-uj.krakow.pl
pubmed:publicationType
Journal Article, Clinical Trial, Validation Studies